CLRB vs. ALGS, ANL, ACRV, TLPH, HYPD, BRNS, QNTM, CELU, SKYE, and ELYM
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Aligos Therapeutics (ALGS), Adlai Nortye (ANL), Acrivon Therapeutics (ACRV), Talphera (TLPH), Hyperion DeFi (HYPD), Barinthus Biotherapeutics (BRNS), Quantum Biopharma (QNTM), Celularity (CELU), Skye Bioscience (SKYE), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs. Its Competitors
Aligos Therapeutics (NASDAQ:ALGS) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
Cellectar Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat Cellectar Biosciences' return on equity.
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Aligos Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.
Cellectar Biosciences has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aligos Therapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Aligos Therapeutics and 2 mentions for Cellectar Biosciences. Aligos Therapeutics' average media sentiment score of 0.24 beat Cellectar Biosciences' score of -0.66 indicating that Aligos Therapeutics is being referred to more favorably in the media.
Aligos Therapeutics presently has a consensus price target of $50.00, indicating a potential upside of 400.50%. Cellectar Biosciences has a consensus price target of $375.00, indicating a potential upside of 8,233.33%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Aligos Therapeutics.
Summary
Aligos Therapeutics beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 10/19/2025 by MarketBeat.com Staff
Free CLRB Stock Alerts